



Part I

chain nodes :

7 8 9 10 11 12 13 14 16

ring nodes :

1 2 3 4 5 6

chain bonds :

2-7 5-16 7-8 7-9 7-10 10-11 11-12 11-13 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-16 7-8 7-9 7-10 10-11 11-12
11-13 13-14

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom

Generic attributes :

16:

Saturation : Unsaturated

STN Columbus

DICTIONARY FILE UPDATES: 21 JUN 2005 HIGHEST RN 852656-52-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****  
*.  
* The CA roles and document type information have been removed from *  
* the IDE default display format and the ED field has been added, *  
* effective March 20, 2005. A new display format, IDERL, is now *  
* available and contains the CA role and document type information. *  
*  
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=>  
L12      STRUCTURE UPLOADED  
  
=> s l12  
SAMPLE SEARCH INITIATED 19:45:32 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -    154 TO ITERATE  
  
100.0% PROCESSED      154 ITERATIONS          35 ANSWERS  
SEARCH TIME: 00.00.01  
  
FULL FILE PROJECTIONS: ONLINE  **COMPLETE**  
                      BATCH   **COMPLETE**  
PROJECTED ITERATIONS:    2336 TO     3824  
PROJECTED ANSWERS:       346 TO      1054
```

L13 35 SEA SSS SAM L12


=> d 113 1 5 10 35

L13 ANSWER 1 OF 35 REGISTRY COPYRIGHT 2005 ACS on STN
RN 688307-45-1 REGISTRY
ED Entered STN: 01 Jun 2004
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-
 (trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H22 F3 N3 O6 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L13 ANSWER 5 OF 35 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 622395-09-9 REGISTRY
 ED Entered STN: 01 Dec 2003
 CN 1,4-Piperidinedicarboxamide, 4-[(4-(4-butoxyphenyl)-1-piperazinyl)sulfonyl]-N4-hydroxy-N1,N1-bis(1-methylethyl)- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H45 N5 O6 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 10 OF 35 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 622394-60-9 REGISTRY
 ED Entered STN: 01 Dec 2003
 CN 2H-Pyran-4-carboxamide, 4-[(4-[1,1'-biphenyl]-4-yl-1-piperazinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H27 N3 O5 S
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




STN Columbus

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 35 OF 35 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 210915-73-4 REGISTRY
 ED Entered STN: 06 Sep 1998
 CN 2-Piperidinecarboxamide, 1-[(4-(4-chloro-2-methylphenyl)-1-piperazinyl)sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C17 H25 Cl N4 O4 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
 L14 STRUCTURE UPLOADED

=> s l14
 SAMPLE SEARCH INITIATED 19:48:28 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 154 TO ITERATE

100.0% PROCESSED 154 ITERATIONS 5 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2336 TO 3824
 PROJECTED ANSWERS: 5 TO 234

L15 5 SEA SSS SAM L14

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	9.94	380.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 19:48:39 ON 22 JUN 2005

STN Columbus

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2005 VOL 142 ISS 26

FILE LAST UPDATED: 21 Jun 2005 (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 115

L16 2 L15

=> d 116 1-2 bib abs hitstr

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2005:409509 CAPLUS

DN 142:463765

TI Preparation of piperidinyl- and piperazinylsulfonylmethyl hydroxamic acids and their use as protease inhibitors

IN Brown, David L.; Grapperhaus, Margaret L.; Kassab, Darren J.; Massa, Mark A.; McDonald, Joseph J.; Mullins, Patrick B.; Rico, Joseph G.; Schmidt, Michelle A.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 644 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005042521	A2	20050512	WO 2004-US36666	20041103	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	PRAI US 2003-700202	A	20031103			

GI

Later



AB Title compds. I [A1-2 = H, alkyl, alkoxyalkyl, etc.; Rx = halo, CN, OH, NO₂, etc.; E2 = CO, COO, OCO, amino, etc.; E3 = alkyl, alkenyl, alkynyl, etc.] are prep'd. For instance, 4-[4-(5-butylpyrazin-2-yl)piperazin-1-yl]sulfonyl]-N-(hydroxy)tetrahydro-2H-pyran-4-carboxamide•2HCl (II) is prep'd. in 8 steps from 1-(tert-butoxycarbonyl)piperazine, 2-chloropyrazine, butylmagnesium chloride, bis(2-bromoethyl)ether and O-(tetrahydro-2H-pyran-2-yl)hydroxyamine. II exhibits Ki = >10,000 nM for MMP-1, 1.52 nM for MMP-2, 0.696 nM for MMP-9, 1.82 nM for MMP-13 and 4290 nM for MMP-14. I are useful for the treatment of conditions assocd. with MMP activity and/or aggrecanase activity.


IT 622385-43-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622385-43-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(2,4-difluorophenyl)-2-thiazolyl]-1-piperazinyl]sulfonyl]tetrahydro-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



* HCl

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2003:875282 CAPLUS

DN 139:364961

TI Preparation of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Brown, David L.; Carroll, Jeffery N.; Chen, Yiyuan; Fobian, Yvette; Freskos, John N.; Gasiecki, Alan F.; Grapperhaus, Margaret; Heintz, Robert M.; Hockerman, Susan L.; Kassab, Darren J.; Khanna, Ish Kumar; Kolodziej, Stephen A.; Massa, Mark; McDonald, Joseph; Mischke, Brent V.; Mischke, Deborah A.; Mullins, Patrick B.; Nagy, Mark; Norton, Monica B.; Rico, Joseph G.; Schmidt, Michelle A.; Stehle, Nathan W.; Talley, John J.; Vernier, William F.; Villamill, Clara I.; Wang, Lijuan Jane; Wynn, Thomas A.

STN Columbus

PA Pharmacia Corporation, USA; et al.

SO PCT Int. Appl., 819 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091247	A2	20031106	WO 2003-US13123	20030425
	WO 2003091247	A3	20040115		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2483314	AA	20031106	CA 2003-2483314	20030425
	US 2005009838	A1	20050113	US 2003-618288	20030425
	EP 1501827	A2	20050202	EP 2003-718529	20030425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009671	A	20050503	BR 2003-9671	20030425
PRAI	US 2002-375598P	P	20020425		
	US 2002-380713P	P	20020515		
	US 2002-392021P	P	20020627		
	WO 2003-US13123	W	20030425		
OS	MARPAT 139:364961				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A1 and A2 together with the C to which they are bonded join to form (un)substituted-heterocyclyl or -carbocyclyl, or A1 and A2 are independently selected from H, alkyl, alkoxyalkyl, alkenyl, alkynyl, etc.; Rx = H, halo, CN, OH, NO₂, alkyl, alkenyl, alkoxy, alkoxyalkyl, heterocyclyl, etc.; Y = N, CH, or CRx; E1 = (un)substituted heteroaryl; E2 = O, CO, C(O)O, OC(O), bond, S, etc.; E3 = halo, CN, (un)substituted-alkyl, -alkenyl, -alkynyl, -heterocyclyl, heterocyclylalkyl, etc.] and their pharmaceutically acceptable salts are prepd. and disclosed as protease inhibitors. Thus, e.g., II·HCl was prepd. with piperazine ring formation occurring via cyclization of 2,2,2-trifluoroethoxyaniline (prepn. given) with N,N-di(2-chloroethyl)methylsulfonamide (prepn. given) to provide piperazinyl intermediate III which was converted in five addnl. steps to the desired product. This invention is directed generally to proteinase (also known as 'protease') inhibitors, and more particularly, inhibitors of matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP') activity and/or aggrecanase activity. In assays to det. inhibition consts. (Ki) against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14, I possessed values ranging from 0.13->10,000. This invention also is directed to compns. of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathol. conditions) assocd. with MMP activity and/or aggrecanase activity.

IT 622393-21-9P 622393-48-0P 622393-63-9P

622394-04-1P


STN Columbus

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compds.; prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)


RN 622393-21-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]-1-piperazinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 622393-48-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(5-propyl-2-pyridinyl)-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 622393-63-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[5-(2-thienyl)-2-pyridinyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 622394-04-1 CAPLUS

CN 4-Piperidinecarboxamide, 4-[[4-(2-benzoxazolyl)-1-piperazinyl]sulfonyl]-N-hydroxy-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




IT 622385-43-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622385-43-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[5-(2,4-difluorophenyl)-2-thiazolyl]-1-piperazinyl]sulfonyl]tetrahydro-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

FULL ESTIMATED COST

10.33

390.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-1.46

-5.11

FILE 'CAOLD' ENTERED AT 19:49:06 ON 22 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

STN Columbus

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
=> s l15  
L17      0 L15  
  
=>
```